Targets of drugs are generally and targets of drugs having side effects are specifically good spreaders of human interactome perturbations

Citations Over TimeTop 14% of 2015 papers

Abstract

Network-based methods are playing an increasingly important role in drug design. Our main question in this paper was whether the efficiency of drug target proteins to spread perturbations in the human interactome is larger if the binding drugs have side effects, as compared to those which have no reported side effects. Our results showed that in general, drug targets were better spreaders of perturbations than non-target proteins, and in particular, targets of drugs with side effects were also better spreaders of perturbations than targets of drugs having no reported side effects in human protein-protein interaction networks. Colorectal cancer-related proteins were good spreaders and had a high centrality, while type 2 diabetes-related proteins showed an average spreading efficiency and had an average centrality in the human interactome. Moreover, the interactome-distance between drug targets and disease-related proteins was higher in diabetes than in colorectal cancer. Our results may help a better understanding of the network position and dynamics of drug targets and disease-related proteins, and may contribute to develop additional, network-based tests to increase the potential safety of drug candidates.

Related Papers

• → Herpesviral Protein Networks and Their Interaction with the Human Proteome(2005)420 cited
• → Mycobacterium tuberculosis interactome analysis unravels potential pathways to drug resistance(2008)102 cited
• → An attempt to understand glioma stem cell biology through centrality analysis of a protein interaction network(2017)5 cited
• → Mapping the Yeast Protein Interaction Network(2008)1 cited
• Biological Network Evolution Hypothesis Applied to Protein Structural Interactome(2003)